New drug application submitted to the FDA for tremors, slowness and stiffness in Parkinson’s disease11/16/2025
https://www.michaeljfox.org/news/new-parkinsons-drug-tavapadon-submitted-fda-review A new drug application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for tavapadon, a once-daily, oral treatment for the tremors, slowness and stiffness — referred to as motor symptoms — that occur in Parkinson’s disease. One of the last steps in the drug development process, an NDA includes information from clinical trials about the safety and effectiveness of a drug to inform FDA decision making on its approval. Webinar - From Declining to Healing: The 3-Step Parkinson's Protocol Improving People's Quality of Life Monday, November 17, 7pm EST - This event is designed to provide you with valuable insights, inspiring stories, and practical tools to navigate the journey with confidence and hope. Here’s why you don’t want to miss it: Gain actionable insights into therapies delivering real results. Hear inspiring stories of symptom improvement and restored hope. Take control of your Parkinson’s care or support your loved one’s journey. – download book Join PD Avengers — Global Alliance to End Parkinson’s Disease We are PD Avengers — Global Alliance to End Parkinson’s — a patient-led movement, uniting people around the world to demand change, drive progress, and ultimately end Parkinson’s disease. Our Why Parkinson’s has been around for over two centuries, yet progress has been too slow. Many living with PD feel unseen, under-resourced, or silenced by systems that aren’t built for urgency. We believe hope isn’t a plan — action is. We unite voices, fuel science, and challenge the status quo because every person with Parkinson’s deserves access to treatments, therapies, and a future without limits.
Comments are closed.
|
